MX2014000480A - Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos. - Google Patents

Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos.

Info

Publication number
MX2014000480A
MX2014000480A MX2014000480A MX2014000480A MX2014000480A MX 2014000480 A MX2014000480 A MX 2014000480A MX 2014000480 A MX2014000480 A MX 2014000480A MX 2014000480 A MX2014000480 A MX 2014000480A MX 2014000480 A MX2014000480 A MX 2014000480A
Authority
MX
Mexico
Prior art keywords
antibody
oligomer
ndpoi
oligomers
capture
Prior art date
Application number
MX2014000480A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Mccampbell
Mary Savage
Paul Shughrue
Abigail Wolfe
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2014000480A publication Critical patent/MX2014000480A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
MX2014000480A 2011-07-13 2012-07-09 Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos. MX2014000480A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (1)

Publication Number Publication Date
MX2014000480A true MX2014000480A (es) 2014-06-23

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000480A MX2014000480A (es) 2011-07-13 2012-07-09 Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos.

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732289B1 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3449926T (pt) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory Composições e métodos de modulação de excisões de smn2 em um sujeito
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
DK3341725T3 (da) * 2015-08-25 2021-09-06 Prothena Biosciences Ltd Fremgangsmåder til detektering af phosphoryleret alpha-synuklein
EP3415912B1 (en) 2016-02-08 2023-03-29 Sysmex Corporation Analyte detection method and reagent kit for detecting analyte
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN114026109A (zh) * 2019-07-05 2022-02-08 株式会社岛津制作所 β淀粉样蛋白的单克隆抗体、和使用该抗体的β淀粉样蛋白相关肽的测定方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2022270901A1 (ko) * 2021-06-25 2022-12-29 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
WO2023034324A2 (en) * 2021-08-30 2023-03-09 The Brigham And Women’S Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
DE60043165D1 (de) 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
CA2561532A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
NZ554725A (en) * 2004-10-25 2009-10-30 Merck & Co Inc Anti-ADDL antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
JP5289963B2 (ja) * 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗addlモノクローナル抗体およびその使用
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
CN102666577A (zh) * 2009-11-24 2012-09-12 前体生物药物股份公司 诊断阿尔茨海默病或轻度认知损害的新的诊断方法
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
BR112013000796B1 (pt) * 2010-07-14 2021-08-31 Merck Sharp & Dohme Corp Anticorpo isolado ou um fragmento de ligação ao antígeno, composição farmacêutica, métodos para inibir a montagem de ligantes difusíveis derivados de ß-amiloide, para inibir a fosforilação de proteína tau em ser202/thr205, para identificar um suposto agente terapêutico, para detectar ligantes difusíveis derivados de ß-amiloide e para diagnosticar uma doença associada aos ligantes difusíveis derivados de ß-amiloide, e, kit para detectar ligantes difusíveis derivados de ß-amiloide

Also Published As

Publication number Publication date
AU2012282825A1 (en) 2014-01-16
EP2732289B1 (en) 2018-04-11
WO2013009667A1 (en) 2013-01-17
US20140120037A1 (en) 2014-05-01
ES2666840T3 (es) 2018-05-08
CN103782171A (zh) 2014-05-07
EP2732286A4 (en) 2015-02-25
AU2012282825B2 (en) 2016-05-26
WO2013009703A3 (en) 2013-03-21
WO2013009703A2 (en) 2013-01-17
JP2014521089A (ja) 2014-08-25
KR20140072019A (ko) 2014-06-12
CN103782171B (zh) 2016-12-14
RU2014105172A (ru) 2015-08-20
BR112014000671A2 (pt) 2017-02-14
DK2732289T3 (en) 2018-05-22
EP2732286A1 (en) 2014-05-21
WO2013009703A8 (en) 2014-01-23
CA2840976A1 (en) 2013-01-17
EP2732289A2 (en) 2014-05-21
US20130052670A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
MX2014000480A (es) Metodo para la deteccion de oligomeros beta amiloide en una muestra de fluidos y usos de los mismos.
AU2005306997B2 (en) Anti-ADDL antibodies and uses thereof
JP6168364B2 (ja) リン酸化タウ凝集体に対する抗体
KR101706789B1 (ko) 진단용 항체 검사법
KR101461538B1 (ko) 생물학적 관심대상의 펩티드 및 단백질의 측정을 위한 고감도 면역검정법 및 키트
CN109073661B (zh) 用于神经学疾病的诊断的测定法
US9310383B2 (en) Antibodies, kit and method for detecting amyloid beta oligomers
JP2020511963A (ja) ヒトアルファ−シヌクレインに対する抗体
US20250020669A1 (en) Methods for detecting neurofilament light chain in plasma and cerebrospinal fluid
TW202346865A (zh) 檢定
CN118369329A (zh) 治疗神经退行性疾病的方法和物质
JP2022527087A (ja) タウオパチーを診断するためのpS396アッセイの使用
US20240358805A1 (en) Methods and materials to treat neurodegenerative disease
TW202434629A (zh) 以抗類澱粉β (ABETA)抗體治療神經病症之方法
JP2018501482A (ja) pGlu−Abetaペプチドの検出のための新規の方法
AU2011204912B2 (en) Anti-ADDL antibodies and uses thereof
TW202344840A (zh) 診斷檢定
WO2026005695A1 (en) Detection of oligomeric tau and soluble tau aggregates
AU2012232964B2 (en) Anti-ADDL antibodies and uses thereof
MX2007004909A (en) Anti-addl antibodies and uses thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal